Shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) were up 1.7% during trading on Wednesday . The stock traded as high as $4.75 and last traded at $4.75, approximately 33,776 shares traded hands during mid-day trading. A decline of 71% from the average daily volume of 116,853 shares. The stock had previously closed at $4.67.

Several equities analysts have commented on BCLI shares. ValuEngine cut shares of Brainstorm Cell Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Maxim Group reaffirmed a “buy” rating and set a $9.00 price objective on shares of Brainstorm Cell Therapeutics in a research report on Friday, November 15th.

The firm has a market capitalization of $107.42 million, a PE ratio of -5.51 and a beta of 1.34. The company’s 50-day moving average price is $4.24 and its 200-day moving average price is $3.94.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Thursday, November 14th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.03). Research analysts expect that Brainstorm Cell Therapeutics Inc will post -0.93 EPS for the current year.

In other news, CFO Preetam Shah acquired 11,600 shares of the firm’s stock in a transaction dated Tuesday, December 24th. The stock was acquired at an average cost of $4.12 per share, with a total value of $47,792.00. 21.20% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in BCLI. BlackRock Inc. lifted its position in shares of Brainstorm Cell Therapeutics by 44.6% during the 2nd quarter. BlackRock Inc. now owns 130,281 shares of the biotechnology company’s stock worth $514,000 after purchasing an additional 40,197 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Brainstorm Cell Therapeutics during the 3rd quarter worth $51,000. Phoenix Holdings Ltd. purchased a new stake in shares of Brainstorm Cell Therapeutics during the 3rd quarter worth $138,000. CFO4Life Group LLC purchased a new stake in shares of Brainstorm Cell Therapeutics during the 4th quarter worth $51,000. Finally, Tower Research Capital LLC TRC lifted its position in shares of Brainstorm Cell Therapeutics by 1,640.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,155 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 10,514 shares during the last quarter. 9.41% of the stock is owned by institutional investors and hedge funds.

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Further Reading: How to build a Fibonacci channel

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.